ChrysCapital, the $2.5 billion Delhi-based private equity major, has earned returns of nearly $400 million from its bets in the pharmaceutical space in the last one year. In the latest deal, the firm has completed its exit from Mankind Pharma, selling its 11% stake for $200 million to Capital International Private Equity Fund in a secondary deal. The deal values the 20-year-old company, which makes both prescription and over the counter drugs, at over $1.8 billion or Rs 12,000 crore.

(Economic Times)